Ginkgo Bioworks Holdings (DNA) Total Liabilities (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Total Liabilities data on file, last reported at $589.9 million in Q1 2026.

• Quarterly Total Liabilities fell 8.69% year-over-year to $589.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $589.9 million (down 8.69% YoY) and the FY2025 annual result came in at $611.1 million, down 7.6% from the prior year.
• Total Liabilities retreated to $589.9 million in Q1 2026, from $611.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $809.6 million in Q1 2023 to a low of $427.2 million in Q2 2022.
• A 5-year average of $639.4 million and a median of $629.4 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 195.51% — and 2023, when it decreased 29.25%.
• Tracing DNA's Total Liabilities over 5 years: stood at $803.0 million in 2022, then declined by 29.25% to $568.2 million in 2023, then advanced by 16.4% to $661.4 million in 2024, then retreated by 7.6% to $611.1 million in 2025, then fell by 3.47% to $589.9 million in 2026.
• The last three Total Liabilities figures came in at $589.9 million (Q1 2026), $611.1 million (Q4 2025), and $629.4 million (Q3 2025), per Business Quant data.